Study of FK463 for the Treatment of Invasive Aspergillosis
- Conditions
- Aspergillosis
- Registration Number
- NCT00036166
- Lead Sponsor
- Astellas Pharma Inc
- Brief Summary
The purpose of the study is to evaluate the safety and efficacy of FK463 in patients with proven or probable invasive infections due to Aspergillus species.
- Detailed Description
This will be an open-label, non-comparative study of intravenous FK463. Enrollment will include at least 100 patients evaluable for efficacy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 326
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (23)
Medizinische Univ.-Klinik
🇦🇹Graz, Austria
Krankenhaus Elisabethinen Linz
🇦🇹Linz, Austria
Hopital Henri Mondor, Service d'Hematologie Clinique
🇫🇷Creteil, France
Hotel Dieu, Service d'Hematologie
🇫🇷Nantes, France
Hopital Saint Louis, Service D'Hematologie/Greffe de Moelle
🇫🇷Paris, France
Hopital Necker Enfants Malades, Service d'Hematologie
🇫🇷Paris, France
Johann Wolfgang Goethe Universitat, Medizinische Klinik III
🇩🇪Frankfurt, Germany
Westpfalz Krankehaus
🇩🇪Kaiserslautern, Germany
Medizinische Klinik und Poliklinik II, Abt. Hamatologie und Onkologie
🇩🇪Leipzig, Germany
Klinikum der Stadt, Medizinische Klinik A
🇩🇪Ludwigshafen, Germany
Scroll for more (13 remaining)Medizinische Univ.-Klinik🇦🇹Graz, Austria